CVS Health Corp Hits 52-Week High Amid Vaccine Access Controversy
CVS Health Corp has reached a 52-week high, with analysts remaining bullish on the company’s future despite controversy over its decision to limit access to the updated Covid vaccine.
2 minutes to read